Considering that inhibition of PARP1 with olaparib resulted in increased BLM expression in PC3 cells, we hypothesized that anti-BLM treatment could enhance the therapeutic efficacy of olaparib in PCa treatment in vivo. The gene discussed is BLM; the disease is posterior cortical atrophy.